Latest financial market updates and expert analysis
Analysis The fairy tale had a good run. For years, Novo Nordisk was the undisputed king of the weight-loss boom, its GLP-1 blockbusters Wegovy and Ozempic commanding premium prices and seemingly...
The gap between XPeng’s operational momentum and its stock price has rarely been wider. The electric vehicle maker just posted...
For nearly eight years, Alnylam has enjoyed something almost unheard of in biotech: a drug with no true rival for...
The numbers coming out of Cupertino last week were, by any conventional measure, exceptional. Revenue hit a record $109.4 billion...
A company that once promised investors hundreds of autonomous kitchen robots in the field by year-end is now targeting just...
The arithmetic of BioNTech’s share repurchase is straightforward on paper: a program of up to 24.9 million shares, capped at...
The tungsten producer’s journey toward a leaner exchange structure is nearly complete. Almonty Industries has now secured approval to delist...
The arithmetic is jarring. Micron Technology closed Friday at 714.70 euros, down 5.86 percent on the day and 21.71 percent...
The numbers tell a story of a company inching back from the edge. SAP’s shares closed Friday at €159.40, up...
The numbers tell a story of two very different timelines. On one hand, Vulcan Energy has just sealed the financial...
The options market is bracing for fireworks. When Novo Nordisk delivers its second-quarter results on August 5, derivatives pricing implies...
